FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
-
Oran Muduroglu , proven medical imaging entrepreneur, to leadU.S. launch of eyonis® LCS -
Established
U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion -
Active discussions underway to establish key clinical partnerships to support broad access across
U.S. lung cancer screening programs -
Webcasts will be held on
February 26, 2026 , to discuss the Company’s recent achievements and upcoming milestones for eyonis® LCS deployment in theU.S.
SOPHIA ANTIPOLIS,
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/
Oran Muduroglu Appointed President of Median eyonis Inc.
“With FDA clearance secured, a defined Medicare reimbursement pathway in place, and a uniquely differentiated solution developed through the exceptional scientific and engineering leadership of our colleagues in
Oran continued, “Our focus now is disciplined execution — aligning payers, distribution partners, and providers around a solution that directly addresses one of the key drivers of non-adherence in lung cancer screening. By reducing uncertainty and false positives, we seek to enable earlier diagnosis, improve physician productivity, and strengthen both the clinical and economic performance of screening programs. We believe eyonis® LCS can materially improve patient confidence and engagement and help health systems focus on patients who truly require intervention. That combination of clinical performance and economic value will drive adoption at scale.”
A
Oran brings more than three decades of experience building, engineering, and scaling enterprise imaging and workflow platforms, consistently translating technical innovation into broad
He led the sale of Cemax to 3M/
Further, as CEO of Medicalis, acquired by Siemens Healthineers in 2017, he led commercialization of a clinical decision support and workflow platform adopted by approximately nine of the top 15 U.S. health systems. In 2018, Alphabet’s Verily recruited him to lead development of a value-based care platform supporting physician groups in managing Medicare Advantage risk.
Across these ventures, Oran has led complex national deployments requiring deep Electronic Medical Records (EMR) and PACS interoperability, rigorous product development, disciplined enterprise sales, and alignment with evolving reimbursement models — experience directly relevant to the
“Oran is a highly respected leader with deep operational rigor and commercialization expertise,”
said
Coordinated Launch Strategy to Drive Rapid Scale-Up in the
During development and validation of eyonis® LCS, the eyonis® team built strong awareness and credibility among radiologists, pulmonologists, and oncologists through presentations at major medical congresses and engagement with leading academic centers. Building on this foundation, the Company is actively engaged in discussions to establish key clinical partnerships designed to enable broad access across
Following eyonis® LCS’ FDA 510(k) clearance announced on
To support the launch strategy, Median eyonis Inc. is expanding its
On
Median plans to broaden commercial adoption of eyonis® LCS by targeting additional non-exclusive distribution agreements with top-tier imaging and cloud technology partners as well as diagnostics partners.
The launch leverages the existing Centers for Medicare and Medicaid Services’ (CMS) reimbursement framework. Following FDA clearance, eyonis® LCS is reimbursable under the New Tech APC pathway, as an initial bridge toward broader and more durable coverage. For 2026, the Medicare Outpatient Prospective Payment System (OPPS) will pay approximately $601–$700 per exam, providing a predictable payment pathway for providers. Approximately 14.5 million Americans meet
The Company expects its first
Webcasts will be held on
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.
These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of
All forward-looking statements in this press release are based on information available to
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218440005/en/
Emmanuelle Leygues
VP,
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press – MAARC
+33 6 87 88 47 26
bruno.arabian@maarc.fr
+33 6 33 67 31 54
nicolas.entz@maarc.fr
Investors - SEITOSEI ACTIFIN
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com
+1 510.417.0612
todd@toddsteincommunications.com
Source:
